Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?
Executive Summary
Companies in heavily regulated industries such as pharmaceuticals often describe congressional investigations under the category of "headline risks": They produce a lot of bad press and a lot of work for the legal, public relations and lobbying arms, but their impact on the core functions of developing and selling drugs is limited
You may also be interested in...
House Energy & Commerce To Continue Foraging Through Vytorin Data
The House Energy & Commerce Committee intends to keep hounding Merck and Schering-Plough for data and internal communications on how the company handled the release of information from three trials on Vytorin (simvastatin/ezetimibe)
House Energy & Commerce To Continue Foraging Through Vytorin Data
The House Energy & Commerce Committee intends to keep hounding Merck and Schering-Plough for data and internal communications on how the company handled the release of information from three trials on Vytorin (simvastatin/ezetimibe)
With A New Administration, The Same FDA? Policy Trends Seem Unlikely To Shift
As the presidential race winds down, another leadership contest is about to heat up: the campaign for FDA commissioner